T2* MRI Analysis for Sarcoma

Not Applicable

Completed

• Conditions: Radiotherapy; Sarcoma; Magnetic Resonance Imaging
• Interventions: Diagnostic Test: T2* Imaging

• Registration Number: NCT03658343
• Lead Sponsor: Bryan Allen

Brief Summary

T2\* imaging is a method to identify labile iron pools in tumor cells. These iron pools may be linked to better treatment outcomes for specific types of therapy. This is a small pilot study to see if radiation therapy changes the amount of iron in a sarcoma tumor.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-08-31
• Study First Submitted QC: 2018-08-31
• Study First Posted: 2018-09-05
• Study Start: 2018-09-18
• Primary Completion: 2022-02-25
• Study Completion: 2022-02-25
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-19
• Last Update Posted: 2025-02-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• pathologically confirmed Sarcoma, by biopsy or excision
• prescribed radiation therapy as per standard of care
• treatment to begin within 5 weeks after surgery or biopsy
• ECOG 0, 1, or 2
• ability and willingness to provide informed consent

Exclusion Criteria

• < 18 years of age

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
T2* Imaging	T2* Imaging	Participants undergo T2\* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.

Primary Outcome Measures

Name	Time	Method
Change in ferric iron levels detected by T2* MRI	baseline and 8 weeks	Change from baseline in Fe3+ iron levels

Secondary Outcome Measures

Name	Time	Method
Change in ferrous iron levels detected by T2* MRI	Baseline and 8 weeks	Change from baseline in Fe2+ iron levels

Trial Locations

Locations (1)

Holden Comprehensive Cancer Center; 🇺🇸 Iowa City, Iowa, United States